AIMS: Nosocomial infections cause significant morbidity and mortality in cancer patients. As a result of their debilitated immune system, cancer patients are likely candidates for colonization with anaerobes. We sought to compare the distribution of nosocomial infections in neutropenic and non-neutropenic cancer patients and to calculate the associated mortality rates. MATERIAL & METHODS: This is the first study to demonstrate a complete microbial spectrum of anaerobes in various infection sites in hospitalized cancer patients. RESULTS: Frequencies of bloodstream infections (BSI), respiratory tract infections (RTI), and GI tract infections (GITI) were significantly higher in neutropenic cancer patients (p < 0.01). Conversely, urinary tract infection (UTI) and skin infection (SI) rates were significantly higher in non-neutropenic cancer patients (p < 0.01). Mortalities attributed to BSI, UTI, RTI, SI, and GITI occured at the respective percentage frequencies of 12.5%, 11.5%, 10.4%, 7.7% and 4.9%. Anaerobes constituted 4.7% of total isolates, and were recovered from SI (66.3%) and GITI (33.6%), but not respiratory tract, urine, or blood. Most anaerobes (79.2%) were isolated from solid-tumor patients. The most common infection in cancer patients was RTI (55.8%), mainly in leukemic patients, followed by SI (18%), only in solid-tumor patients, GITI (9.7%), BSI (9.4%), and UTI (7.1%). The most frequent isolates of Fusobacterium necrophorum (32.7%) and Eubacterium lentum (23.8%) were mostly recovered from solid-tumor patients. These were followed by Clostridium perfringens (11.9%), Clostridium difficile (10.9%), Eubacterium limosum (5.9%), and Veillonella parvula (5%). CONCLUSION: Control measures are needed to minimize risks of nosocomial infection outbreaks by anaerobes. Continuous monitoring of the presence of anaerobes in various infection sites in hospitalized cancer patients is needed in order to be able to provide the best supportive care for cancer patients.
AIMS: Nosocomial infections cause significant morbidity and mortality in cancerpatients. As a result of their debilitated immune system, cancerpatients are likely candidates for colonization with anaerobes. We sought to compare the distribution of nosocomial infections in neutropenic and non-neutropenic cancerpatients and to calculate the associated mortality rates. MATERIAL & METHODS: This is the first study to demonstrate a complete microbial spectrum of anaerobes in various infection sites in hospitalized cancerpatients. RESULTS: Frequencies of bloodstream infections (BSI), respiratory tract infections (RTI), and GI tract infections (GITI) were significantly higher in neutropenic cancerpatients (p < 0.01). Conversely, urinary tract infection (UTI) and skin infection (SI) rates were significantly higher in non-neutropenic cancerpatients (p < 0.01). Mortalities attributed to BSI, UTI, RTI, SI, and GITI occured at the respective percentage frequencies of 12.5%, 11.5%, 10.4%, 7.7% and 4.9%. Anaerobes constituted 4.7% of total isolates, and were recovered from SI (66.3%) and GITI (33.6%), but not respiratory tract, urine, or blood. Most anaerobes (79.2%) were isolated from solid-tumorpatients. The most common infection in cancerpatients was RTI (55.8%), mainly in leukemicpatients, followed by SI (18%), only in solid-tumorpatients, GITI (9.7%), BSI (9.4%), and UTI (7.1%). The most frequent isolates of Fusobacterium necrophorum (32.7%) and Eubacterium lentum (23.8%) were mostly recovered from solid-tumorpatients. These were followed by Clostridium perfringens (11.9%), Clostridium difficile (10.9%), Eubacterium limosum (5.9%), and Veillonella parvula (5%). CONCLUSION: Control measures are needed to minimize risks of nosocomial infection outbreaks by anaerobes. Continuous monitoring of the presence of anaerobes in various infection sites in hospitalized cancerpatients is needed in order to be able to provide the best supportive care for cancerpatients.
Authors: Tobias Rachow; Verena Schlüter; Sibylle Bremer-Streck; Udo Lindig; Sebastian Scholl; Peter Schlattmann; Michael Kiehntopf; Andreas Hochhaus; Marie von Lilienfeld-Toal Journal: Infection Date: 2017-05-17 Impact factor: 3.553
Authors: Kevin Chen; Keval Desai; Soundari Sureshanand; Kerin Adelson; Jeremy I Schwartz; Cary P Gross; Sarwat I Chaudhry Journal: JCO Oncol Pract Date: 2021-01-08
Authors: Leyre Zubiri; Rachel P Rosovsky; Aditya Bardia; Kerry L Reynolds; Meghan J Mooradian; A J Piper-Vallillo; Justin F Gainor; Ryan J Sullivan; Daniel Marte; Genevieve M Boland; Xin Gao; Ephraim P Hochberg; David P Ryan; Corey McEwen; Minh Mai; Tanya Sharova; Tara E Soumerai Journal: Oncologist Date: 2021-05-18 Impact factor: 5.837
Authors: Cindy B Yeoh; Kathleen J Lee; Elizabeth F Rieth; Renee Mapes; Anna V Tchoudovskaia; Gregory W Fischer; Luis E Tollinche Journal: Anesth Analg Date: 2020-07 Impact factor: 5.108